<?xml version="1.0" encoding="UTF-8"?>
<list list-type="roman-lower">
 <list-item>
  <p>comparative quality characterization based on previously established critical attributes (
   <xref rid="B30" ref-type="bibr">30</xref>);
  </p>
 </list-item>
 <list-item>
  <p>defining the potential impact of identified differences in the biodistribution, biological activity/efficacy, and safety using modeling and simulation approaches (
   <xref rid="B31" ref-type="bibr">31</xref>);
  </p>
 </list-item>
 <list-item>
  <p>pre-clinically confirming 
   <italic>in vitro</italic> (potentially followed by 
   <italic>in vivo</italic>) the anticipated consequences of quality-related differences (
   <xref rid="B32" ref-type="bibr">32</xref>);
  </p>
 </list-item>
 <list-item>
  <p>clinically confirming the preclinical findings through comparative efficacy (and safety) studies (
   <xref rid="B33" ref-type="bibr">33</xref>);
  </p>
 </list-item>
 <list-item>
  <p>establishing a post-marketing surveillance program for the safety of the putatively approved similar NBCD.</p>
 </list-item>
</list>
